Several months after acquiring the rights to TNX-1900 oxytocin nasal spray for the treatment of migraine headaches from Trigemina, Tonix Pharmaceuticals announced that it has acquired an exclusive license to technology from the University of Geneva for the use of oxytocin to treat insulin resistance and related conditions such as obesity. The company has not yet … [Read more...] about Tonix to develop intranasal oxytocin for the treatment of insulin resistance and obesity
Medical
Novan selects Catalent for development of intranasal berdazimer sodium
Catalent will supply development services for an intranasal formulation of Novan's berdazimer sodium for COVID-19, the companies said. Berdazimer sodium is a nitric oxide-releasing polymer based on Novan's Nitricil platform, and the company is developing topical gel formulations for the treatment of viral dermatological infections, including molluscum and genital … [Read more...] about Novan selects Catalent for development of intranasal berdazimer sodium
PrEP Biopharm to initiate trial of PrEP-001 intranasal Poly I:C against respiratory viruses
Johnson & Johnson spinout PrEP Biopharm said that it is ready to initiate a real-world trial of its PrEP-001 intranasal "viral RNA surrogate" against common respiratory viruses after the successful completion of a toxicology study in dogs. The trial is designed to evaluate the efficacy PrEP-001, an intranasal dry powder formulation of polyinosinic:polycytidylic … [Read more...] about PrEP Biopharm to initiate trial of PrEP-001 intranasal Poly I:C against respiratory viruses
Phase 1b trial of TFF’s voriconazole DPI in asthma patients is underway
TFF Pharmaceuticals announced that the first subjects have been dosed in a Phase 1b clinical trial of its dry powder voriconazole, which it is developing for the treatment of invasive pulmonary aspergillosis. The trial is expected to enroll 30 adult asthma patients and will evaluate two doses of voriconazole, 40 mg and 80 mg, versus placebo. In September 2020, the … [Read more...] about Phase 1b trial of TFF’s voriconazole DPI in asthma patients is underway
Codagenix and SIIPL initiate Phase 1 trial of COVI-VAC intranasal vaccine
Codagenix and vaccine manufacturer Serum Institute of India (SIIPL) have initiated a Phase 1 trial of COVI-VAC single-dose intranasal, live attenuated vaccine against SARS-CoV-2 after receiving approval from the MHRA, the companies said. Like Codagenix's CodaVax-RSV vaccine, which is also in Phase 1 development, COVI-VAC is based on Codagenix's SAVE codon … [Read more...] about Codagenix and SIIPL initiate Phase 1 trial of COVI-VAC intranasal vaccine
UofL researchers get $8.5 million from US Department of Defense for Q-Griffithsin nasal spray development
The US Department of Defense is providing $8.5 million to fund development of a Q-Griffithsin (Q-GRFT) nasal spray at the University of Louisville, the university said. The funding will support the PREVENT-CoV project for development of a once-daily nasal spray for the prevention of viral infections through a Phase 1 study. Researchers say that because they already … [Read more...] about UofL researchers get $8.5 million from US Department of Defense for Q-Griffithsin nasal spray development
Savara halts development of AeroVanc, Apulmiq
Savara Pharmaceuticals has announced that it is halting development of its AeroVanc vancomycin DPI after the Phase 3 AVAIL trial of AeroVanc for the treatment of MRSA lung infections in cystic fibrosis patients failed to meet its primary endpoint. The AVAIL trial, which was initiated in 2017, failed to show statistically significant improvement in lung function or a … [Read more...] about Savara halts development of AeroVanc, Apulmiq
Regeneron partners with Penn to study feasibility of intranasal delivery of its antibody cocktail for COVID-19
Regeneron Pharmaceuticals is collaborating with researchers at the University of Pennsylvania (Penn) to study the feasibility of intranasal delivery of Regeneron’s casirivimab and imdevimab antibody cocktail for the prevention of COVID-19, the university said. The antibody cocktail, which recently received emergency use authorization from the FDA, is currently given … [Read more...] about Regeneron partners with Penn to study feasibility of intranasal delivery of its antibody cocktail for COVID-19
Codagenix completes dosing in Phase 1 trial of its intranasal RSV vaccine
Codagenix announced that it has completed dosing in a Phase 1 clinical trial of its intranasal CodaVax-RSV vaccine for the prevention of respiratory syncytial virus (RSV). According to Codagenix, its SAVE (Synthetic Attenuated Virus Engineering) codon deoptimization platform, "results in genetically stable vaccine strains that can engender robust immune responses and … [Read more...] about Codagenix completes dosing in Phase 1 trial of its intranasal RSV vaccine
Synairgen turns to Parexel for help with Phase 3 trial of inhaled interferon beta for COVID-19
Parexel announced that Synairgen has signed a collaboration agreement with Parexel Biotech for a Phase 3 trial of Synairgen's SNG001 nebulized interferon-beta-1a for the treatment of COVID-19. In July 2020, Synairgen announced positive results from a Phase 2 trial of SNG001 in COVID-19 patients hospitalized in the UK. The Phase 3 SG018 trial is expected to enroll 900 … [Read more...] about Synairgen turns to Parexel for help with Phase 3 trial of inhaled interferon beta for COVID-19